4P-Pharma will attend the upcoming BIO2022, in San Diego (US), June 13-16. Revital Rattenbach, our chairwoman, Roselina Lam, our business development and licensing-in manager are glad to attend the event, as part of the Business France delegation. To learn more about us, our pipeline and discuss future partnership, please feel free to connect with us via the partnering platform or by e-mail. We are&hellip
4P-Pharma will attend the upcoming ALS Drug Development 2022 starting next week, May 24-26 in Boston (US). Célia Rabhi, our PhD student working on our 4P019 project on neurodegenerative diseases, will attend it. To learn more about us, please feel free to connect with us. For further information on the event, click here.
The ARVO annual meeting organized by the Association for Research in Vision and Ophthalmology starts next week, from 2022 May 1st-4th in Denver (USA). We are glad to announce the participation of Lola Vigouroux Sautet, our junior Project Manager of 4P020, our dry AMD To learn more about us and 4P020, please feel free to connect with us. She is looking forward&hellip
4P-Pharma is present at BIO Europe Spring 2022! Join us at the digital event. Roselina Lam, our Business Development and Licensing–in Manager, will attend the upcoming BIO Europe Spring on 2022, March 28th-31st delivered digitally. To learn more about us, our pipeline and discuss future partnership, please feel free to connect with us via the partnering platform or by e-mail. She is looking forward&hellip
Challenges magazine highlights 4P-Pharma. Revital Rattenbach, 4P-Pharma’s CEO, outlines our major advances and our partners for drug regeneration dedicated to patients affected by untreated serious diseases. To see the complete article in French, here is the link.
4P-Pharma signs a partnership with QuantHealth, a data science start-up taking a unique in-silico approach to clinical trial simulations based on broad real-world data (RWD) and deep molecular drug data. Together, we will conduct in silico clinical trials of our lead drug candidates. Our partnership will start with the in-silico simulation of the phase II clinical trial of&hellip